Note 3. Selected Balance Sheet Data:

Inventories:

Inventories consist of (in thousands):

​

​

⁽¹⁾ Finished goods inventory of $5,722 and $5,456 included within other long-term assets in the respective March 31, 2022 and June 30, 2021, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

​

Property and Equipment:

Property and equipment consist of (in thousands):

​

​

Intangible Assets:

Intangible assets consist of (in thousands):

​

​

Changes to the carrying amount of net intangible assets for the period ended March 31, 2022 consist of (in thousands):

​

​

The estimated future amortization expense for intangible assets as of March 31, 2022 is as follows (in thousands):

​

​

⁽¹⁾ As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of FY'22.

Goodwill:

Changes to the carrying amount of goodwill for the period ended March 31, 2022 consist of (in thousands):

​

​

⁽¹⁾As discussed in Note 4, there was an adjustment to the preliminary allocation of the Asuragen acquisition opening balance sheet during the measurement period.

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2021. No indicators of impairment were identified as part of our assessment.

During the quarter ended September 30, 2021, the Company combined the management of the Exosome Diagnostics and Asuragen reporting units, both of which are included in the Diagnostics and Genomics operating segment. In conjunction with the combination of the reporting units, a qualitative goodwill impairment assessment was performed. The qualitative assessment identified no indicators of impairment.

As disclosed in Note 1, the Company identified a triggering event and a goodwill impairment charge of $8.3 million in the second quarter of fiscal 2022. No additional triggering events or items beyond the upcoming Eminence liquidation were identified during the quarter ended March 31, 2022. The impairment of the Eminence goodwill is the only impairment of goodwill recorded since the adoption of Financial Accounting Standards Board ("FASB") ASC 350 guidance for goodwill and other intangibles on July 1, 2002.